PharmAsia News’ India Pharma Roundup: Biological E., Suven Life Sciences, Strides Arcolab, Dabur, Glenmark
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Biological E., which has a clinical trial network of 13,000 doctors and hospitals across India, signed an option and license agreement with U.S.-based Heparinex and Choncept to work on development of new methods to make anti-coagulant chondroitin derived from fermentation of recombinant bacteria to replace chondroitin sourced from beef and other animal by-products
You may also be interested in...
PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.
PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.
Contaminant Discovered In Chinese-Produced Heparin API
U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant